Introduction: Sarcopenic obesity and its association with nonalcoholic fatty liver disease (NAFLD) is under-recognized by many healthcare providers in Western medicine due to the lack of awareness and diagnostic guidelines. The result is delayed recognition and treatment, which leads to further health deterioration and increased healthcare costs. Sarcopenic obesity is characterized by the presence of increased fat mass in combination with muscle catabolism related to chronic inflammation and/or inactivity. Previous research has recommended evaluating body composition and physical function performance to adequately diagnose sarcopenic obesity. Body composition analysis can be performed by imaging applications through magnetic resonance imaging, computed tomography, and dual-energy x-ray absorptiometry. Due to the cost of each device and radiation exposure for patients as evidenced in all three modalities, bioelectrical impedance analysis offers a noninvasive approach capable of providing quick and reliable estimates of lean body and fat mass. Methods and Results: This review analyzes the current evidence-based literature, indicating a lower skeletal muscle mass and increased visceral adipose tissue correlation to the advancement of fibrosis in fatty liver disease. Conclusion: Given the substantial promising research conducted in predominantlyAsian populations regarding body tissue distribution and NAFLD, additional prospective research is needed to extend these findings in Western populations.
The Food and Drug Administration (FDA) good laboratory pradice (GLP) inspections in fiscal year 2003 increased signif;cantly at a level of 7l% over the previous year. A review and analysis of recently issued FDA warning letters for nonclinical laboratory studies found that the two major GLP compliance deficiencies were study director responsibility and authority (21 CFR 558.33) and the quality assurance unit (21 CFR 958.35). This article raiews the background of the GLP regulations, the FDA GLP inspection program, the importance of interpreting the GLP regulations, the use of published FDA references to ensure the cowect and efective interpretations of the regulations, and the specific interpretations of the GLP requirements for the study director and quality assurance unit.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.